Peer Review History

Original SubmissionFebruary 3, 2023
Decision Letter - Maemu Petronella Gededzha, Editor

PONE-D-23-03115An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNAPLOS ONE

Dear Dr. Poovorawan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 06 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Maemu Petronella Gededzha, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"This study was part of a viral hepatitis elimination project in Thailand and was supported by the National Research Council of Thailand, Thailand Grand Challenge Fund (RES_64_058_30_020), Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital. We are grateful to all staff from the sub-district health-promoting centers, district hospitals, and general hospitals in Phetchabun province. Without their collaboration, this research study may not have been possible. "

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"NO - Include this sentence at the end of your statement: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

Additional Editor Comments:

When preparing your revised manuscript, you are asked to carefully consider the reviewer comments which are attached

Major:

i. It is not clear whether the samples used in this study are part of the samples tested positive in their previous study (Reference 13) or it’s a new cohort.

ii. If it is a new cohort please describe the cohort in details and indicate how many samples were screened by Anti-HCV?

iii. What is the sensitivity and specificity of the HCVcAg in this cohort?

iv. Include phylogenetic tree and indicate which method was used to construct the tree

v. Figure 1 resolution is poor and it is difficult to interpret the results

vi. Elaborate further in the discussion about the mutations detected in the core and treatment choice.

Minor comments:

vii. Please list the names, sources of all reagents used in the methodology.

viii. Reference the methods used eg. Sanger sequencing.

ix. Line 81-84-Write minutes and seconds in full.

x. Line 94: Which instrument was used? Eg i2000.

xi. Line 96-97: Where the specimens with concentration values ≥ 3.00 fmol/L to < 10.00 fmol/L retested in duplicate? What was the outcome?

xii. Line 106: Include the viral of the samples not detected.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an absolutely important piece of data for HCV detection and eradication. The research cautions against the use of HCVcAg quantification as the sole method to test for HCV infection as some HCV genotypes with low levels of HCVcAg might results in false-negative detection of HCV.

A few comments to take note of and rectify or clarify:

Line 81 - mention the genotype of the reference strain.

Line 85 - Give an explanation for the use of two different amplification methods.

Line 89 - Accession numbers not available yet on GeneBank.

Line 93 - State the upper value first followed by the lower limit.

Line 111- Table 1 - add a column with the average HCV RNA levels.

Line 120 - 123 - Rephrase and avoid long sentences for clarity.

Line 150-151 - Rectify the sentence construction - plural.

Reviewer #2: The authors provide in this interesting work several evidences supporting the substitution of amino acid of HCV core antigen and the fact that it limit its use as reliable measure of HCV infection. They further showed that HCV RNA can be an alternative marker to be used. However there are several aspects to be improved in order to present convincing evidences and conclusions.

Major points

1. The introduction does not provide sufficient background of the study, it is therefor important that the author must write a comprehensive introduction.

2. The abstract needs some improvement

Minor points

3. Page 5, briefly explain the ARCHITECT HCV Ag assay

4. Page 6, line 117-18 need to be re-visited, the statement does not make sense at all. The explanation for the results need to be re-visited, especially on page 6, 7, it does not make sense at all. Results must be self-explanatory

5. It is important to discuss the method used to do phylogenetic analysis obtained

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Hazel Tumelo Mufhandu

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Response to reviewers

Editor Comments:

Question: It is not clear whether the samples used in this study are part of the samples tested positive in their previous study (Reference 13) or it’s a new cohort.

Answer: All samples used in this study were leftover from a previous population study, Pratedrat P; PlosOne 2023: PMID: 36656832 (reference 19). We have revised this section in material and method in lines 85-90.

Question: If it is a new cohort, please describe the cohort in details and indicate how many samples were screened by Anti-HCV?

Answer: Samples in this study are part of a new cohort (reference 19). Briefly, in a total of 170,163 residents in Phetchabun province, Thailand, 10,621 tested positive for anti-HCV RDT. Among the HCV serological positive, 3,930 samples were positive for qualitative HCV RNA testing. Of these, 1,027 available samples were further tested for the viral load to fulfill the Thai Universal Health Coverage eligibility criteria for HCV treatment. A total of 354 serum samples in this study were the leftover samples from the 1027 samples. We have cited the new cohort reference in material and method (lines 85-90).

Question: What is the sensitivity and specificity of the HCVcAg in this cohort?

Answer: The manufacturer's instructions indicated that the sensitivity and specificity of the HCVcAg assay at a 3 fmol/L cut-off were 97.8% and 99.5%, respectively (lines 148-152). While the sensitivity and specificity of HCVcAg were not determined in the current cohort, a previous study on Thai HCV patients reported that the HCVcAg assay had a diagnostic performance of 99% sensitivity, 100% specificity, 100% positive predictive value, 97% negative predictive value, and 99% accuracy in predicting HCV active infection (Wasitthankasem R; Peer J 2017: PMID: 29134150). This information was discussed in lines 254-262.

Question: Include phylogenetic tree and indicate which method was used to construct the tree.

Answer: The HCV genotyping was classified by phylogenetic analysis using the Neighbor-joining approach with Kimura’s 2 parameters model (lines 121-133). The phylogenetic trees are included in the supplement figures.

Question: Figure 1 resolution is poor and it is difficult to interpret the results.

Answer: We have improved the resolution accordingly.

Question: Elaborate further in the discussion about the mutations detected in the core and treatment choice.

Answer: We have discussed this point accordingly in lines 254-267.

Question: Please list the names and sources of all reagents used in the methodology.

Answer: We have included information about the reagents utilized in the Materials and Methods section, in lines 111-116.

Question: Reference the methods used eg. Sanger sequencing.

Answer: The information about the methods has been included in the Materials and Methods section, especially in lines 115-116 and 121-133.

Question: Lines 81-84, write minutes and seconds in full.

Answer: We have edited as a suggestion (lines 112-115).

Question: Line 94: Which instrument was used? Eg i2000.

Answer: The instrument used in this study is the Abbott Architect i1000SR analyzer (line 138)

Question: Line 96-97: Where the specimens with concentration values ≥ 3.00 fmol/L to < 10.00 fmol/L retested in duplicate? What was the outcome?

Answer: To ensure accuracy, samples with a concentration ranging from ≥ 3.00 fmol/L to < 10.00 fmol/L underwent duplicate testing. All retested samples were found to be ≥ 3.00 fmol/L and therefore were assigned as reactive for HCVcAg (lines 148-150).

Question: Line 106: Include the viral of the samples not detected.

Answer: The results for two samples with HCV genotype 6 and HCV RNA levels of 4.04 x 103 and 8.85 x 103 IU/ml have been included in lines 162-163, indicating that despite their high RNA levels, they tested non-reactive for HCVcAg with values below 3 fmol/L.

Reviewer #1

This is an absolutely important piece of data for HCV detection and eradication. The research cautions against the use of HCVcAg quantification as the sole method to test for HCV infection as some HCV genotypes with low levels of HCVcAg might results in false-negative detection of HCV. A few comments to take note of and rectify or clarify:

Question: Line 81 - mention the genotype of the reference strain.

Answer: The primer positions were assigned according to the HCV prototype reference, H77, with accession number NC_004102 (lines 108-110).

Question: Line 85 - Give an explanation for the use of two different amplification methods.

Answer: The initial 76 samples were genotyped using primer sets that were too short of analyzing the 3D structure of the HCV core amino acid sequence. Furthermore, these samples could not be re-amplified for further PCR analysis. As a result, new primer sets were utilized for PCR amplification in the remaining 268 samples, which allowed for the analysis of a more extended nucleotide sequence and the 3D structure of the HCV core region (lines 100-105).

Question: Line 89 - Accession numbers not available yet on GeneBank.

Answer: The nucleotide sequences generated from this study were deposited in the GenBank database under accession numbers OQ351363-OQ351716. As per the GenBank policy, the sequence data will be made publicly available one year after submission to the GenBank repository or upon manuscript publication.

Question: Line 93 - State the upper value first, followed by the lower limit.

Answer: We have edited accordingly in line 137.

Question: Line 111- Table 1 - add a column with the average HCV RNA levels.

Answer: The average HCV RNA levels have been added to Table 1.

Question: Line 120 - 123 - Rephrase and avoid long sentences for clarity.

Answer: The sentence has been revised accordingly (lines 173-178).

Question: Line 150-151 - Rectify the sentence construction - plural.

Answer: The sentence has been revised accordingly in lines 204-207.

Reviewer #2

The authors provide in this interesting work several evidences supporting the substitution of amino acid of HCV core antigen and the fact that it limits its use as reliable measure of HCV infection. They further showed that HCV RNA can be an alternative marker to be used. However, there are several aspects to be improved in order to present convincing evidences and conclusions.

Question: The introduction does not provide sufficient background of the study. It is therefore important that the author must write a comprehensive introduction.

Answer: The background knowledge has been included in more detail in the introduction (lines 50-62 and 67-73).

Question: The abstract needs some improvement

Answer: The abstract has been improved accordingly.

Question: Page 5, briefly explain the ARCHITECT HCV Ag assay

Answer: The ARCHITECT HCV Ag assay details were described in lines 141-152.

Question: Page 6, line 117-18 need to be re-visited, the statement does not make sense at all. The explanation for the results needs to be re-visited, especially on page 6, 7, it does not make sense at all. Results must be self-explanatory.

Answer: The sentence has been revised accordingly (lines 173-178).

Question: It is important to discuss the method used to do phylogenetic analysis obtained.

Answer: Phylogenetic trees were constructed using the Neighbor-joining approach using Kimura’s 2 parameters with 1000 bootstrap. The methodology of phylogenetic analysis used in this study was added in lines 121-133 and Figure S1-S3.

Attachments
Attachment
Submitted filename: Response_to_Reviewer.docx
Decision Letter - Maemu Petronella Gededzha, Editor

An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA

PONE-D-23-03115R1

Dear Dr. Poovorawan,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Maemu Petronella Gededzha, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Hazel Tumelo Mufhandu

Reviewer #2: Yes: Shonisani Wendy Limani

**********

Formally Accepted
Acceptance Letter - Maemu Petronella Gededzha, Editor

PONE-D-23-03115R1

An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA

Dear Dr. Poovorawan:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Maemu Petronella Gededzha

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .